Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents: A Voxelwise and Genome-Wide Association Study.
Adolescent
Adult
Case-Control Studies
Cation Transport Proteins
/ biosynthesis
Female
Genetic Predisposition to Disease
/ genetics
Genome-Wide Association Study
Gray Matter
/ pathology
Humans
Hypertrophy
/ genetics
Magnetic Resonance Imaging
Male
Mutation, Missense
/ genetics
Neuroimaging
Putamen
/ pathology
Schizophrenia
/ genetics
Siblings
Journal
JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
pubmed:
17
1
2019
medline:
18
2
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
Deviation from normal adolescent brain development precedes manifestations of many major psychiatric symptoms. Such altered developmental trajectories in adolescents may be linked to genetic risk for psychopathology. To identify genetic variants associated with adolescent brain structure and explore psychopathologic relevance of such associations. Voxelwise genome-wide association study in a cohort of healthy adolescents aged 14 years and validation of the findings using 4 independent samples across the life span with allele-specific expression analysis of top hits. Group comparison of the identified gene-brain association among patients with schizophrenia, unaffected siblings, and healthy control individuals. This was a population-based, multicenter study combined with a clinical sample that included participants from the IMAGEN cohort, Saguenay Youth Study, Three-City Study, and Lieber Institute for Brain Development sample cohorts and UK biobank who were assessed for both brain imaging and genetic sequencing. Clinical samples included patients with schizophrenia and unaffected siblings of patients from the Lieber Institute for Brain Development study. Data were analyzed between October 2015 and April 2018. Gray matter volume was assessed by neuroimaging and genetic variants were genotyped by Illumina BeadChip. The discovery sample included 1721 adolescents (873 girls [50.7%]), with a mean (SD) age of 14.44 (0.41) years. The replication samples consisted of 8690 healthy adults (4497 women [51.8%]) from 4 independent studies across the life span. A nonsynonymous genetic variant (minor T allele of rs13107325 in SLC39A8, a gene implicated in schizophrenia) was associated with greater gray matter volume of the putamen (variance explained of 4.21% in the left hemisphere; 8.66; 95% CI, 6.59-10.81; P = 5.35 × 10-18; and 4.44% in the right hemisphere; t = 8.90; 95% CI, 6.75-11.19; P = 6.80 × 10-19) and also with a lower gene expression of SLC39A8 specifically in the putamen (t127 = -3.87; P = 1.70 × 10-4). The identified association was validated in samples across the life span but was significantly weakened in both patients with schizophrenia (z = -3.05; P = .002; n = 157) and unaffected siblings (z = -2.08; P = .04; n = 149). Our results show that a missense mutation in gene SLC39A8 is associated with larger gray matter volume in the putamen and that this association is significantly weakened in schizophrenia. These results may suggest a role for aberrant ion transport in the etiology of psychosis and provide a target for preemptive developmental interventions aimed at restoring the functional effect of this mutation.
Identifiants
pubmed: 30649180
pii: 2720422
doi: 10.1001/jamapsychiatry.2018.4126
pmc: PMC6450291
doi:
Substances chimiques
Cation Transport Proteins
0
SLC39A8 protein, human
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-445Subventions
Organisme : Medical Research Council
ID : MC_PC_17228
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_QA137853
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N000390/1
Pays : United Kingdom
Références
Cereb Cortex. 2016 Sep;26(9):3732-43
pubmed: 26250778
Neuroimage. 2016 Nov 1;141:273-281
pubmed: 27453157
Neuropsychopharmacology. 2017 Mar;42(4):933-940
pubmed: 27782128
Schizophr Res. 2007 Jan;89(1-3):59-71
pubmed: 17071057
Nat Genet. 2016 May;48(5):481-7
pubmed: 27019110
Brain. 2007 Mar;130(Pt 3):678-92
pubmed: 17303593
J Child Psychol Psychiatry. 2006 Oct;47(10):987-93
pubmed: 17073977
Biol Psychiatry. 2012 Jan 15;71(2):169-77
pubmed: 22078303
Neuropsychopharmacology. 2013 Feb;38(3):533-9
pubmed: 23132271
Am J Psychiatry. 2015 Oct;172(10):995-1003
pubmed: 26085040
Schizophr Res. 2003 Nov 1;64(1):53-62
pubmed: 14511801
Nat Neurosci. 2018 Mar;21(3):315-323
pubmed: 29403031
J Neurochem. 2011 Oct;119(2):275-82
pubmed: 21848658
Nat Neurosci. 2016 Nov;19(11):1523-1536
pubmed: 27643430
Horm Behav. 2013 Jul;64(2):195-202
pubmed: 23624012
Biol Psychiatry. 2008 Nov 1;64(9):774-81
pubmed: 18486104
Am J Med Genet B Neuropsychiatr Genet. 2018 Mar;177(2):274-283
pubmed: 28557351
Biochem Pharmacol. 2014 Oct 15;91(4):426-35
pubmed: 25130547
Elife. 2018 May 30;7:
pubmed: 29846171
Psychol Med. 2012 Jul;42(7):1475-83
pubmed: 22030695
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
Neuroimage. 2014 Aug 1;96:67-72
pubmed: 24705201
J Neurosci. 2017 Mar 22;37(12):3402-3412
pubmed: 28242797
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Nat Neurosci. 1999 Oct;2(10):861-3
pubmed: 10491603
Neuropsychol Rev. 2015 Mar;25(1):27-46
pubmed: 25672928
Nature. 2014 Jul 24;511(7510):421-7
pubmed: 25056061
Trends Neurosci. 2011 Jun;34(6):316-25
pubmed: 21459462
Schizophr Bull. 2013 Sep;39(5):1129-38
pubmed: 23042112
Neuroscience. 2014 Dec 5;281:147-63
pubmed: 25255932
J Clin Invest. 2018 Feb 1;128(2):826-833
pubmed: 29337306
Front Psychiatry. 2017 Nov 20;8:245
pubmed: 29209237
Genes Brain Behav. 2014 Nov;13(8):733-42
pubmed: 25311829
Lancet Psychiatry. 2015 Mar;2(3):258-270
pubmed: 26359903
Dev Psychopathol. 2013 Nov;25(4 Pt 2):1325-45
pubmed: 24342843
Lancet. 2009 Jan 17;373(9659):234-9
pubmed: 19150704
Schizophr Res. 2015 Dec;169(1-3):178-185
pubmed: 26527246
Twin Res Hum Genet. 2012 Jun;15(3):351-71
pubmed: 22856370
Transl Psychiatry. 2014 Jan 07;4:e339
pubmed: 24399042
Neuroreport. 1998 Feb 16;9(3):425-30
pubmed: 9512384
Neuroimage. 2010 Nov 15;53(3):1160-74
pubmed: 20171287
Psychopharmacology (Berl). 2018 Aug;235(8):2221-2232
pubmed: 29717334
Hum Mol Genet. 2016 Sep 15;25(18):4117-4126
pubmed: 27466201
Mol Pharmacol. 2006 Jul;70(1):171-80
pubmed: 16638970
Biofactors. 2010 Mar-Apr;36(2):117-24
pubmed: 20333753
Mol Psychiatry. 2015 Aug;20(8):1011-6
pubmed: 25224261
Schizophr Bull. 2013 Jan;39(1):33-42
pubmed: 22282454
Cent Eur Neurosurg. 2011 Aug;72(3):133-7
pubmed: 20857373
Neuron. 2014 Feb 5;81(3):484-503
pubmed: 24507187
Psychiatry Res. 1995 Nov 10;61(4):209-29
pubmed: 8748466
J Clin Invest. 2017 Jun 1;127(6):2407-2417
pubmed: 28481222
Biol Psychiatry. 2008 Mar 1;63(5):465-74
pubmed: 17689500
Mol Psychiatry. 2016 Oct;21(10):1460-6
pubmed: 26782053
Mol Psychiatry. 2010 Dec;15(12):1128-39
pubmed: 21102431
JAMA Psychiatry. 2015 May;72(5):490-9
pubmed: 25785435
PLoS One. 2013 Jun 11;8(6):e64065
pubmed: 23776438
Nature. 2015 Apr 9;520(7546):224-9
pubmed: 25607358
Nature. 2015 Jul 30;523(7562):588-91
pubmed: 26176920
Behav Brain Res. 2008 Aug 22;191(2):190-201
pubmed: 18486243
Neuroepidemiology. 2003 Nov-Dec;22(6):316-25
pubmed: 14598854
Brain Cogn. 2010 Feb;72(1):6-15
pubmed: 19796863
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Int J Epidemiol. 2017 Apr 1;46(2):e19
pubmed: 27018016
Cell Rep. 2013 Feb 21;3(2):386-400
pubmed: 23403290
Nat Rev Cardiol. 2017 Oct;14(10):577-590
pubmed: 28569269
Mol Psychiatry. 2015 Feb;20(2):263-74
pubmed: 24514566
Biol Psychiatry. 2015 Sep 15;78(6):403-12
pubmed: 25802081
C R Biol. 2002 Jun;325(6):665-72
pubmed: 12360853